Literature DB >> 21700579

CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease.

R Perneczky1, A Tsolakidou, A Arnold, J Diehl-Schmid, T Grimmer, H Förstl, A Kurz, P Alexopoulos.   

Abstract

OBJECTIVE: To explore if soluble amyloid precursor proteins (sAPP) in CSF improve the identification of patients with incipient Alzheimer disease (AD) in a group of patients with mild cognitive impairment (MCI).
METHODS: A cohort study with follow-up assessments of 58 patients with MCI with baseline CSF sampling was conducted: 21 patients had progressed to probable AD (MCI-AD), 27 still had MCI, 8 had reverted to normal (MCI-NAD), and 2 patients with frontotemporal dementia (FTD) were excluded. Sixteen additional patients with FTD were included to explore the specificity of the CSF markers. CSF concentrations of sAPPα, sAPPβ, tau, and Aβ(1-42) were measured with sensitive and specific ELISAs. Associations between diagnostic status, CSF protein concentrations, and other patient characteristics were explored using multiple logistic regression analyses with stepwise variable selection. The optimal sensitivity and specificity of the best models were derived from receiver operating characteristic curves.
RESULTS: The MCI-AD group had significantly higher sAPPβ concentrations than the MCI-NAD and the FTD groups. A combination of sAPPβ, tau, and age differentiated the MCI-AD and the MCI-NAD groups with a sensitivity of 80.00% and a specificity of 81.00%. The best model for the differentiation of the MCI-AD and the FTD groups included sAPPβ and tau, and showed a sensitivity of 95.20% and a specificity of 81.20%. Aβ(1-42) and sAPPα did not significantly contribute to the models.
CONCLUSION: These findings suggest that sAPPβ may be clinically useful, and superior to Aβ(1-42), in the early and differential diagnosis of incipient AD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700579     DOI: 10.1212/WNL.0b013e318221ad47

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  42 in total

1.  SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer’s disease.

Authors:  Liang-Hao Guo; Christine Westerteicher; Xin-Hui Wang; Martina Kratzer; Amalia Tsolakidou; Meizi Jiang; Timo Grimmer; Simon M Laws; Panagiotis Alexopoulos; Hideaki Bujo; Alexander Kurz; Robert Perneczky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09       Impact factor: 5.270

2.  Alzheimer disease: a novel biomarker to detect early-stage Alzheimer disease.

Authors:  Katy Malpass
Journal:  Nat Rev Neurol       Date:  2011-07-19       Impact factor: 42.937

Review 3.  Body fluid biomarkers in Alzheimer's disease.

Authors:  Huan Lu; Xi-Chen Zhu; Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  Ann Transl Med       Date:  2015-04

4.  Distinct in vivo roles of secreted APP ectodomain variants APPsα and APPsβ in regulation of spine density, synaptic plasticity, and cognition.

Authors:  Max C Richter; Susann Ludewig; Alex Winschel; Tobias Abel; Charlotte Bold; Leonie R Salzburger; Susanne Klein; Kang Han; Sascha W Weyer; Ann-Kristina Fritz; Bodo Laube; David P Wolfer; Christian J Buchholz; Martin Korte; Ulrike C Müller
Journal:  EMBO J       Date:  2018-04-16       Impact factor: 11.598

Review 5.  Restoring Soluble Amyloid Precursor Protein α Functions as a Potential Treatment for Alzheimer's Disease.

Authors:  Ahsan Habib; Darrell Sawmiller; Jun Tan
Journal:  J Neurosci Res       Date:  2016-08-17       Impact factor: 4.164

6.  CSF sAPPα and sAPPβ levels in Alzheimer's Disease and Multiple Other Neurodegenerative Diseases: A Network Meta-Analysis.

Authors:  Wei Tang; Yan Wang; Juan Cheng; Jie Yao; Yu-You Yao; Qiang Zhou; Shi-He Guan
Journal:  Neuromolecular Med       Date:  2019-08-14       Impact factor: 3.843

7.  Plasma proteomics for the identification of Alzheimer disease.

Authors:  Liang-Hao Guo; Panagiotis Alexopoulos; Stefan Wagenpfeil; Alexander Kurz; Robert Perneczky
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

8.  Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease.

Authors:  Robert Perneczky; Panagiotis Alexopoulos
Journal:  Alzheimers Dement       Date:  2013-11-13       Impact factor: 21.566

9.  Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder.

Authors:  Joel Jakobsson; Henrik Zetterberg; Kaj Blennow; Carl Johan Ekman; Anette G M Johansson; Mikael Landén
Journal:  Neuropsychopharmacology       Date:  2012-11-06       Impact factor: 7.853

Review 10.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Anne M Fagan; Richard J Perrin
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.